Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-PDA: Selective Early Ibuprofen for PDA
NCT05011149Phase 3Recruiting
- Sponsor
- IWK Health
- Start
- Jan 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ibuprofen in patent ductus arteriosus (PDA), sponsored by IWK Health. Started Jan 2022; status: recruiting.
02
Drugs
ibuprofen
03
Conditions
patent ductus arteriosus (PDA)
Beyond the preview
Go deeper on NCT05011149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011149.